Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Felicitas Hitz et al.|Blood|2010Cited by 24